(Total Views: 236)
Posted On: 05/26/2021 10:00:18 AM
Post# of 36542
I do want to give my opinion on this and take it for what it is worth. With all the concerns about the NGIO listing, the Class A vs Class B shares and the impact it has on everyone, it would really benefit Generex / NGIO and the management of both companies to try to smooth things over and change up the way they present things and start trying to do things a little bit more ON TIME and placate their shareholders and future investors a bit.
If the manufacturing run date is finished, provide information. Give an update on the Excellegen financing. Give an update on the clinical trial supply.
Stop with the old business as usual. That was what people have been complaining about for years and on top of that, the Class A / Class B shares mess did not help. So, make some positive changes and start producing results that people can hang their hats on instead of the same old, same old.
Be a much better company that communicates.
If the manufacturing run date is finished, provide information. Give an update on the Excellegen financing. Give an update on the clinical trial supply.
Stop with the old business as usual. That was what people have been complaining about for years and on top of that, the Class A / Class B shares mess did not help. So, make some positive changes and start producing results that people can hang their hats on instead of the same old, same old.
Be a much better company that communicates.
(3)
(0)Scroll down for more posts ▼
